Pasar al contenido principal

Resultados relacionados

Resultados totales (Incluyendo duplicados): 3
Encontrada(s) 1 página(s)

Minerva. Repositorio Institucional de la Universidad de Santiago de Compostela
Publicación Artículo científico (JournalArticle)

Effects of two different peptides on pentylenetetrazole-induced seizures in larval zebrafish

  • Araujo Fernández, Jhonathan Angel
  • Moura, Thatiane Cristina de
  • Fernández Vila, Sabela
  • Rubiolo Gaytán, Juan Andrés
  • López-Díaz, Iñaki
  • Learte Aymamí, Soraya
  • Vázquez Sentís, Marco Eugenio
  • Mayán, María D.
  • Sánchez Piñón, Laura
  • Maurer-Morelli, Claudia Vianna
Epilepsy is a common and severe neurological disease characterized by spontaneous and recurrent seizures. Although anti-seizure treatments are effective for most patients, approximately 30% remain pharmacoresistant. Moreover, uncontrolled seizures are associated with increased health risks and shortened life expectancy in individuals with refractory epilepsy. Preclinical studies play a crucial role in drug discovery, and the zebrafish (Danio rerio) have been successfully employed for this purpose. In this study, we utilized the zebrafish PTZ-induced seizure model to evaluate the effects of two peptides on seizure responses: Tripeptide (p-BTX-I) and the CX2 (a Cx43derivated peptide). Zebrafish larvae at 6 days post-fertilization were pre-treated with these peptides at various concentrations, depending on their experimental groups, 24h prior to seizure induction. We assessed seizure frequency, quantified swimming activity, measured transcript levels of genes related to inflammation and apoptosis (il1b, tnfa, cox1, cox2a, il6, casp3a, casp9, baxa, bcl2a, and c-fos), and analyzed the biodistribution of both peptides. Our results indicate that the Tripeptide exhibited anti-inflammatory and anti-apoptotic effects, particularly through reducing the expression of il1b and casp9. CX2 pre-treatment significantly downregulated inflammatory markers (il1b, il6, tnfa, and cox1). Biodistribution analysis confirmed that the CX2 peptide reached the zebrafish brain, suggesting a direct role in modulating seizure-related pathways. Our findings demonstrate that Tripeptide and CX2 peptides can modulate gene expression and mitigate molecular response associated with epileptic seizures in the zebrafish brain. These peptides thus represent promising candidates for future research aimed at developing novel anti-epileptic therapies. However, additional studies are required to evaluate their long-term efficacy, elucidate underlying mechanisms of action, and explore potential translational applications.
RUC. Repositorio da Universidade da Coruña
Publicación Artículo científico (JournalArticle)

Cx43 enhances response to BRAF/MEK inhibitors by reducing DNA repair capacity

  • Varela Vázquez, Adrián
  • Guitián-Caamaño, Amanda
  • Carpintero-Fernández, Paula
  • Carneiro Figueira, Alexander
  • Álvarez, Vanesa
  • Varela-Eirín, Marta
  • Calleja-Chuclá, Teresa
  • Bravo López, Susana Belén
  • Vidal, Anxo
  • Sendón Lago, Juan José
  • Rodríguez-Candela-Mateos, Marina
  • Caeiro, José Ramón
  • Sanz-Moreno, Victoria
  • Aasen, Trond
  • González Blanco, Miguel
  • Sabio, Guadalupe
  • Quindós-Varela, María
  • Rivas, Carmen
  • Santamaría, David
  • Fernández-Lozano, Carlos
  • Fonseca, Eduardo
  • Huertas, Pablo
  • Sánchez-Laorden, Berta
  • Alabert, Constance
  • Mayán, María D.
[Abstract]: BRAF and MEK inhibitors (BRAF/MEKi) have radically changed the treatment landscape of advanced BRAF mutation-positive tumours. However, limited efficacy and emergence of drug resistance are major barriers for successful treatments. Here, by using relevant preclinical models, we find that Connexin43 (Cx43), a protein that plays a role in cell-to-cell communication, enhances the effectiveness of BRAF/MEKi by recruiting DNA repair complexes to lamin-associated domains and promoting persistent DNA damage and cellular senescence. The nuclear compartmentalization promoted by Cx43 contributes to genome instability and synthetic lethality caused by excessive DNA damage, which could provide a therapeutic approach for these tumours to overcome drug resistance. Based on these findings, we designed a drug combination using small extracellular vesicles (sEVs) to deliver the full-Cx43 in combination with the BRAF/MEKi. This study reveals Cx43 as a regulator of DNA repair and BRAF/MEKi response, highlighting the therapeutic potential that this approach could eventually have in the clinic to overcome the limitations of current therapies and improve treatment outcomes for patients with advanced BRAF mutant tumours., This work was supported in part through funding from a grant from Ministry of Science, Innovation and Universities (MICIU/AEI/10.13039/501100011033): PID2022−137027OB-I00 ERDF/EU and a grant from the Joint Transnational Call for Proposals for ‘European Innovative Research & Technological Development Projects in Nanomedicine’ EURONANOMED III (AC21_2/00026) (to M.D.M.); a grant from Xunta de Galicia (IN607B2020/12) (to M.D.M.); a grant from HORIZON-MSCA-2023-SE-01 (101183034) and FET-OPEN-Future and Emerging Technologies (to M.D.M.) and from EU HORIZON-CSA 101079489. TWINFLAG (to M.D.M.). A.V.-V., P.C.-F. and M.V.-E. were funded with post-doctoral fellowship (IN606B 2022/002; INB606B 2017/014 and IN606C 2021/006; IN606B-2019/004) from Xunta de Galicia. A.G.-C. was funded with a predoctoral fellowship (FIS20/00310) from ISCIII. A.C.-F. was funded with a predoctoral fellowship (IN606A 2022/038) from Xunta de Galicia. T.A. acknowledges funding from Instituto de Salud Carlos III, grant PI21/00470 co-financed by the European Regional Development Fund (ERDF). V.S.M. was supported by the Institute of Cancer Research; Cancer Research UK (CRUK) C33043/A24478; Breast Cancer Now as part of Programme Funding to the Breast Cancer Now Toby Robins Research Centre; Barts Charity; Worldwide Cancer Research 22-0329 and UKRI grant reference EP/X033392., Xunta de Galicia; IN607B2020/12, Xunta de Galicia; IN606B 2022/002, Xunta de Galicia; INB606B 2017/014, Xunta de Galicia; IN606C 2021/006, Xunta de Galicia; IN606B-2019/004, Xunta de Galicia; IN606A 2022/038, United Kingdom. Cancer Research UK (CRUK); C33043/A24478
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Cx43 enhances response to BRAF/MEK inhibitors by reducing DNA repair capacity

  • Varela-Vázquez, Adrián
  • Guitián-Caamaño, Amanda
  • Carpintero-Fernández, Paula
  • Carneiro-Figueira, Alexander
  • Álvarez, Vanesa
  • Varela-Eirín, Marta
  • Calleja-Chuclá, Teresa
  • Bravo-López, Susana B.
  • Vidal, Anxo
  • Sendón-Lago, Juan
  • Rodriguez-Candela Mateos, Marina
  • Caeiro, José R.
  • Sanz-Moreno, Victoria
  • Aasen, Trond
  • Blanco, Miguel G.
  • Sabio, Guadalupe
  • Quindós, María
  • Rivas, Carmen
  • Santamaria, David
  • Fernández-Lozano, Carlos
  • Fonseca, Eduardo
  • Huertas Sánchez, Pablo
  • Sánchez-Laorden, Berta
  • Alabert, Constance
  • Mayán, María D.
BRAF and MEK inhibitors (BRAF/MEKi) have radically changed the treatment landscape of advanced BRAF mutation-positive tumours. However, limited efficacy and emergence of drug resistance are major barriers for successful treatments. Here, by using relevant preclinical models, we find that Connexin43 (Cx43), a protein that plays a role in cell-to-cell communication, enhances the effectiveness of BRAF/MEKi by recruiting DNA repair complexes to lamin-associated domains and promoting persistent DNA damage and cellular senescence. The nuclear compartmentalization promoted by Cx43 contributes to genome instability and synthetic lethality caused by excessive DNA damage, which could provide a therapeutic approach for these tumours to overcome drug resistance. Based on these findings, we designed a drug combination using small extracellular vesicles (sEVs) to deliver the full-Cx43 in combination with the BRAF/MEKi. This study reveals Cx43 as a regulator of DNA repair and BRAF/MEKi response, highlighting the therapeutic potential that this approach could eventually have in the clinic to overcome the limitations of current therapies and improve treatment outcomes for patients with advanced BRAF mutant tumours., This work was supported in part through funding from a grant from Ministry of Science, Innovation and Universities (MICIU/AEI/10.13039/501100011033): PID2022−137027OB-I00 ERDF/EU and a grant from the Joint Transnational Call for Proposals for ‘European Innovative Research & Technological Development Projects in Nanomedicine’ EURONANOMED III (AC21_2/00026) (to M.D.M.); a grant from Xunta de Galicia (IN607B2020/12) (to M.D.M.); a grant from HORIZON-MSCA-2023-SE-01 (101183034) and FET-OPEN-Future and Emerging Technologies (to M.D.M.) and from EU HORIZON-CSA 101079489. TWINFLAG (to M.D.M.). A.V.-V., P.C.-F. and M.V.-E. were funded with post-doctoral fellowship (IN606B 2022/002; INB606B 2017/014 and IN606C 2021/006; IN606B-2019/004) from Xunta de Galicia. A.G.-C. was funded with a predoctoral fellowship (FIS20/00310) from ISCIII. A.C.-F. was funded with a predoctoral fellowship (IN606A 2022/038) from Xunta de Galicia. T.A. acknowledges funding from Instituto de Salud Carlos III, grant PI21/00470 co-financed by the European Regional Development Fund (ERDF). V.S.M. was supported by the Institute of Cancer Research; Cancer Research UK (CRUK) C33043/A24478; Breast Cancer Now as part of Programme Funding to the Breast Cancer Now Toby Robins Research Centre; Barts Charity; Worldwide Cancer Research 22-0329 and UKRI grant reference EP/X033392. We thank members of the CellCOM group for helpful technical suggestions, Biobank A Coruña for collecting tissue samples, Arantxa Tabernero (INCYL, University of Salamanca) for kindly providing the human Cx43 plasmid used in this study. The group of Dr. María Pardo (Obesidomic Group, IDIS, Santiago de Compostela, Spain) for advise us in the first step of sEVs isolation and characterisation, the group of Dr. José Luis Labandeira (Cell and Molecular Neurobiology of Parkison´s disease, CiMUS, Santiago de Compostela, Spain) for help with ex vivo assays, the Dr. Julián Yañez and Dr. María Luz Díaz (NEUROVER Group, University of Coruña, Spain), Dr. Ángel Fernández (Department of Cellular Pathology, Hospital La Reina, Ponferrada, Spain), IDIS facility (María Otero and Dr. García Caballero, Santiago de Compostela, Spain) and María C. Vázquez (Biobank A Coruña, Spain) for the knowledge in the area of anatomical pathology and tissue histology. The Genomics Unit CNIC (Dr. Alberto Benguría and team) for their help and support. We would like to thank Dr. Mercedes Peleteiro, head of the Flow Cytometry Services at CINBIO, for her helpful technical support and data analysis using CytoFlex S. Dr. Laura Tomás (CINBIO, University of Vigo) for her help and support with RNA-seq data submission to SRA. We would also like to acknowledge Marina Rodríguez-Candela Mateos (CellCOM group) for transfecting a cell line with that a vector and database analysis, Dr. Silvia Penuela (University of Western Ontario, Canada) and Dr. Edward Leithe (Oslo University Hospital HE, Norway) for providing vectors and antibodies. Although these were not ultimately included in the results of this manuscript, their valuable input significantly contributed to our research. Some images were created using the academic BioRender account under license number 866291E9., Peer reviewed